Follow The Filings

VNRX VolitionRX

VolitionRX earnings company data as of 4:48 AM ET 10/23

History

2 periods, newest first. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 12 Nov EPS — — —
Rev — — —
FY2026 Q2 13 Aug EPS — -0.85 —
Rev — $1.4M —

Insider trades

Open-market buys and sales by VNRX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All VNRX insider trades
  • $7,000 bought by 1 insider
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Cameron John Reynolds CEO
    Buy
    $7,000 20,000 shares at $0.3500 +0.8% to stake
    Traded Nov 17, 2025 Filed Nov 17, 2025
  2. Cameron John Reynolds CEO
    Buy
    $56K 110,000 shares at $0.5100 +4.5% to stake
    Traded Oct 14, 2025 Filed Oct 15, 2025
  3. Guy Archibald Innes Director
    Buy
    $49K 96,153 shares at $0.5100 +9.9% to stake
    Traded Oct 14, 2025 Filed Oct 15, 2025
  4. Timothy I Still Director
    Buy
    $25K 48,076 shares at $0.5100 +3.2% to stake
    Traded Oct 14, 2025 Filed Oct 15, 2025

Also filed in the last 12 months, not counted as buying or selling: 27 stock grants and 17 share withholdings for taxes.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
8-K 3.02
SCHEDULE 13D/A —
8-K 3.02
8-K 8.01,9.01
SCHEDULE 13D —
8-K 1.01,9.01
8-K 3.02
8-K 3.02
SCHEDULE 13G/A —
8-K 2.02,9.01
10-Q FORM 10-Q
8-K 3.02
8-K 5.03,5.07,9.01
8-K 3.02
8-K 1.01,8.01,9.01
424B5
424B5
DEF 14A
8-K 1.01
SCHEDULE 13G/A —
8-K 5.02
8-K 2.02,9.01
10-Q FORM 10-Q
10-K/A FORM 10-K/A
8-K 3.03,5.03,9.01

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.